CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ULTRA-DD aims to validate new drug discovery targets by generating high-quality research tools, particularly chemical probes and antibodies. The project emphasizes collaboration among academic and industrial partners to ensure open access to resources and knowledge for the broader research community.
ULTRA-DD (Unrestricted Leveraging of Targets for Research Advancement and Drug Discovery) will be an European-wide, highly collaborative and inclusive consortium, to validate new targets for drug discovery by (1) generating high quality
research tools, with an emphasis on chemical probes; (2) generating the chemical probes in the most cost-effective manner, using structure-guided methods and harnessing the chemical libraries and medicinal chemistry skills of the EFPIA
participants; (3) testing t…
NOVARTIS PHARMA AG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Germany, Leverkusen
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
Switzerland, Zuerich
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
